Eisai Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 79

Eisai Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Eisai Inc. - Product Pipeline Review - H2 2011” provides data on the Eisai Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Eisai Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Eisai Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Eisai Inc. - Brief Eisai Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Eisai Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Eisai Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Eisai Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Eisai Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Eisai Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Eisai Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Eisai Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Eisai Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Eisai Inc.; Eisai Inc. - Key Therapeutics; Eisai Inc. - Pipeline Overview and Promising Molecules; Eisai Inc. - News; Eisai Inc. - Latest Updates; Eisai Inc. - Pipeline; Eisai Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Eisai Inc. Snapshot
Eisai Inc. Overview
Key Information
Key Facts
Eisai Inc. – Research and Development Overview
Key Therapeutic Areas
Eisai Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Eisai Inc. – Pipeline Products Glance
Eisai Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Eisai Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Eisai Inc.–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Eisai Inc. – Drug Profiles
Cinitapride
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Cyclophosphamide + Eribulin Mesylate
Product Description
Mechanism of Action
R&D Progress
E6201
Product Description
Mechanism of Action
R&D Progress
E7016 + Temozolomide
Product Description
Mechanism of Action
R&D Progress
E7050 + Cisplatin + Capecitabine
Product Description
Mechanism of Action
R&D Progress
E7050 + E7080
Product Description
Mechanism of Action
R&D Progress
E7080 + Dacarbazine
Product Description
Mechanism of Action
R&D Progress
Eribulin Mesylate + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Eribulin Mesylate + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
HGS Oncology Program
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
MORAb-022
Product Description
Mechanism of Action
R&D Progress
SyB L-0501
Product Description
Mechanism of Action
R&D Progress
Eisai Inc. – Pipeline Analysis
Eisai Inc. – Pipeline Products by Therapeutic Class
Eisai Inc. - Pipeline Products By Target
Eisai Inc. – Pipeline Products by Route of Administration
Eisai Inc. – Pipeline Products by Molecule Type
Eisai Inc. – Recent Pipeline Updates
Eisai Inc. - Dormant Projects
Eisai Inc. – Company Statement
Eisai Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 31, 2006: Eisai Starts Marketing Severe Chronic Pain Agent Prialt in the UK and Germany
Mar 31, 1999: FDA Approves Fragmin for Prevention of Deep Vein Thrombosis (DVT) Following Hip Replacement Surgery.
Nov 30, 2010: Eisai Submits Marketing Authorization Application In Japan For Insomnia Treatment SEP-190
Oct 30, 2009: Eisai And Quintiles Enter Into A Strategic Collaboration To Develop Eisai’s Anticancer Compounds
Mar 30, 1999: Ligand and Ferrer Entered Into agreement for Marketing and Distribution of Panretin.
Apr 29, 1996: Pharmacia And Kissei To Copromote Fragmin
Sep 28, 2005: Eisai Announces Exclusive In-License of All U.S. Promotional Rights for Fragmin, an Injectable Anti-Clotting Agent
Jun 28, 2010: Eisai And Morphotek Initiate Phase I Clinical Trial Of MORAb-022 For Treatment Of Rheumatoid Arthritis In Europe
Dec 27, 2007: U.S. District Court Decision about Eisai's Legal Action over Aricept ODT ANDA Filing
Sep 27, 2004: FDA Grants Orphan Drug Designation for Gliadel Wafer(Polifeprosan 20 With Carmustine Implant) for Treatment of Brain Cancer
Feb 27, 2003: Approves Guilford's Gliadel As First-line Therapy For Glioma.
Feb 26, 2003: FDA Approves Expanded Use Of Gliadel Wafer (Polifeprosan 20 With Carmustine Implant) For Primary Malignant Brain Cancer
Oct 25, 2006: Eisai Announces Completion of Acquisition of Four Oncology-Related Products from Ligand
Oct 25, 2000: Guilford Gets Back All Rights To Gliadel Wafer From Aventis.
Jan 25, 2006: Eisai Inc. Assumes U.S. Distribution for Fragmin-New Capability Expands Eisai's Presence in Hospital Market
Sep 24, 1996: GLIADEL Wafer Receives FDA Clearance as First Localized Treatment For Most Rapidly Fatal Type of Brain Cancer
Sep 24, 1996: Implantable wafer is first treatment to deliver chemotherapy directly to tumor site.
Feb 24, 1992: Mgi Pharma Submits New Drug Application For Salagen
Feb 23, 1995: Chiron Therapeutics and MGI Pharma Inc. announce approval of Salagen tablets in the United Kingdom.
Oct 21, 2004: FDA Approves Orally Disintegrating Tablet Formulation of ARICEPT for the Treatment of Patients with Mild to Moderate Alzheimer's Disease
Mar 20, 2006: Elan Closes Sale of Rights to Prialt In Europe to Eisai
Jul 17, 2000: European CPMP Recommendes the approval of Ligand's Panretin Gel
Jul 17, 1995: US Bioscience Signs Euro Marketing Deal
Nov 15, 2010: Eisai Receives FDA Approval For Halaven Injection For Treatment Of Metastatic Breast Cancer
Nov 15, 2000: MGI Pharma Purchasing Hexalen® from MedImmune for Ovarian Cancer
Nov 15, 1995: Fragmin during instability in coronary artery disease (frisc) study
Jul 15, 1996: New Dosage Strength now available for once-daily fragmin
Jan 14, 1991: U.S. Bioscience grants Kanebo Ltd. marketing rights for anticancer compound. (Hexalen, anti-ovarian cancer agent) (Japan)
Mar 11, 2010: Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT From Elan
May 10, 2010: Azur Pharma Announces the Closing of the Acquisition of PRIALTCNS/Pain Specialty Infrastructure End-User Sales of $20 Million in 2009
Feb 09, 2006: Eisai Agrees To Acquire Severe Chronic Pain Agent Prialt For Europe From Elan
Feb 09, 2006: Elan to Sell Rights to Prialt in Europe to Eisai
May 08, 1995: Eli Lilly Canada; Hexalen and Ethyol
Mar 08, 1999: Pharmacia & Upjohn and Centocor Sign Co-Promotion Agreement for Fragmin in Unstable Angina.
Sep 07, 2006: Eisai Acquires Four Oncology-Related Products from Ligand
Sep 07, 2006: Eisai Acquires Four Oncology-Related Products from Ligand
Jun 06, 2005: Convenient New Formulation of Aricept Now Available for the Treatment of Mild-to-Moderate Alzheimer's Disease
Apr 06, 2009: Eisai and Nobelpharma Sign License Agreement for GLIADEL WAFER in Japan
Jan 06, 2000: Alfa Wassermann has agreement with Ligand for the marketing and distribution of Ontak, Targretin and Panretin
Aug 04, 2006: Eisai Commences U.S. Legal Action over Aricept ODT ANDA Filing
Dec 03, 2008: Ranbaxy to market USFDA approved drug GLIADEL for treatment of brain tumor in India
Aug 03, 2004: Guilford Pharmaceuticals Gliadel Wafer Assigned New Drg Designation
Feb 03, 1999: Panretin receives FDA approval
May 02, 2007: FDA Approves New Indication for FRAGMIN- FDA Approves FRAGMIN as First Low-Molecular-Weight-Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Nov 01, 1995: Fragmin, a new once-daily low-molecular-weight heparin, is introduced for prevention of deep vein thrombosis following abdominal surgery
Financial Deals Landscape
Eisai Inc., Deals Summary
Eisai Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Eisai Announces Completion of Acquisition of Four Oncology Related Products from Ligand
Partnerships
Eisai Enters Into A Drug Discovery Collaboration With FORMA Therapeutics
Aestus Therapeutics Enters Into Co-Development Agreement With Eisai
Arena Enters Into Co-Marketing Agreement With Eisai For Lorcaserin
Helsinn Therapeutics Enters Into Co-Promotion Agreement With Eisai
Salix Pharmaceuticals Enters Into Co-Promotion Agreement With Eisai
Cardinal Health Signs An Agreement With Eisai
Licensing Agreements
Helsinn Healthcare Extends Licensing Agreement With Eisai
Brain Science Institute Enters Into Licensing Agreement With Eisai
Eisai Enters Into License Agreement With Janssen Pharmaceutica For ACIPHEX
Acquisition
Eisai Acquires Morphotek
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Eisai Inc. – Pipeline by Therapy Area and Indication, H2 2011
Eisai Inc. – Pipeline by Stage of Development, H2 2011
Eisai Inc. – Monotherapy Products in Pipeline, H2 2011
Eisai Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Eisai Inc. – Phase III, H2 2011
Eisai Inc. - Phase II, H2 2011
Eisai Inc. - Phase I, H2 2011
Eisai Inc. - Pipeline By Therapeutic Class, H2 2011
Eisai Inc. - Pipeline By Target, H2 2011
Eisai Inc. – Pipeline By Route of Administration, H2 2011
Eisai Inc. – Pipeline By Molecule Type, H2 2011
Eisai Inc. – Recent Pipeline Updates, H2 2011
Eisai Inc. - Dormant Developmental Projects, H2 2011
Eisai Inc., Other Locations, H2 2011
Eisai Inc., Subsidiaries, H2 2011
Eisai Inc., Deals Summary, H2 2011
Eisai Announces Completion of Acquisition of Four Oncology Related Products from Ligand
Eisai Enters Into A Drug Discovery Collaboration With FORMA Therapeutics
Aestus Therapeutics Enters Into Co-Development Agreement With Eisai
Arena Enters Into Co-Marketing Agreement With Eisai For Lorcaserin
Helsinn Therapeutics Enters Into Co-Promotion Agreement With Eisai
Salix Pharmaceuticals Enters Into Co-Promotion Agreement With Eisai
Cardinal Health Signs An Agreement With Eisai
Helsinn Healthcare Extends Licensing Agreement With Eisai
Brain Science Institute Enters Into Licensing Agreement With Eisai
Eisai Enters Into License Agreement With Janssen Pharmaceutica For ACIPHEX
Eisai Acquires Morphotek

List of Figures
Eisai Inc. – Pipeline by Therapy Area and Indication, H2 2011
Eisai Inc. – Pipeline by Stage of Development, H2 2011
Eisai Inc. – Monotherapy Products in Pipeline, H2 2011
Eisai Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Eisai Inc. – Pipeline By Therapeutic Class, H2 2011
Eisai Inc. - Pipeline By Target, H2 2011
Eisai Inc. – Pipeline By Route of Administration, H2 2011
Eisai Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Analysis of Google Inc
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model